Journal of Clinical Oncology
Articles in this Issue
ASCENT-03: Efficacy by biomarker subgroup with sacituzumab govitecan (SG) vs chemotherapy (chemo) in participants (pts) with previously untreated advanced triple-negative breast cancer (TNBC) who are not candidates for PD-(L)1 inhibitors (PD-[L]1i).
1014 Background: SG demonstrated significant and clinically meaningful progression-free survival (PFS) improvement vs chem...
Temporal trends and demographic disparities in cardiovascular disease (CVD) and hepatocellular carcinoma (HCC)–related mortality in the United States, 1999–2020: CDC WONDER Analysis.
e16360 Background: Hepatocellular Carcinoma (HCC) is the fifth most common cause of cancer worldwide. Five-year survival o...
Real-world treatment patterns, genomic profiling access, and survival outcomes in advanced lung adenocarcinoma: A retrospective cohort analysis from a resource-limited setting.
e20722 Background: Real-world management of advanced NSCLC in LMICs is constrained by low biomarker testing rates(PD-L1, N...
Final analysis of the biomarker-directed, randomized, phase 2 KEYNOTE-495/KeyImPaCT study of pembrolizumab (P)–based combination therapy for non–small cell lung cancer (NSCLC).
8584 Background: KEYNOTE-495/KeyImPaCT (NCT03516981) evaluated 3 P-based regimens in participants (pts) with advanced NSCL...
Post-hoc efficacy and biomarker analysis of elraglusib plus gemcitabine/nab-paclitaxel versus chemotherapy alone in metastatic pancreatic ductal adenocarcinoma.
4213 Background: Elraglusib (9-ING-41), a glycogen synthase kinase-3β (GSK-3β) inhibitor, has multimodal antitumor activit...
Safety and efficacy of pembrolizumab plus lenvatinib as first-line therapy in non-small cell lung cancer: A systematic review and meta-analysis of randomized controlled trials.
e20634 Background: Pembrolizumab, an anti-PD-1 antibody, and Lenvatinib, a multi-kinase inhibitor, were identified as pote...
Real-world distribution of antibody–drug conjugate (ADC)–associated adverse events (AEs) in breast cancer patients: An EPIC Cosmos database analysis.
e13079 Background: AEs among ADC-treated breast cancer patients (BCPs) are associated with targeted antigens (TROP2, HER2)...
AI-powered social media listening of oncologist conversations at ASCO 2025.
9045 Background: Major oncology congresses generate extensive expert-driven discussion on social media around clinical tri...
Application of unsupervised genetic clustering to identify biologically distinct cholangiocarcinoma subtypes with differential survival.
4025 Background: Cholangiocarcinoma (CCA) is a genetically heterogeneous malignancy for which current anatomic and histolo...
Real-world efficacy and safety of iruplinalkib in <i>ALK</i> -positive advanced lung adenocarcinoma patients previously treated with lorlatinib.
e20730 Background: Treatment options after lorlatinib failure remain limited in patients with anaplastic lymphoma kinase (...
Long-term safety results and adverse event (AE) management recommendations in patients with ER+/HER2− metastatic breast cancer (mBC) receiving prifetrastat, a first-in-class KAT6 inhibitor, at the recommended phase 3 dose (RP3D) of 5 mg once-daily (QD).
1068 Background: Prifetrastat (PF-07248144) is a first-in-class, potent, and selective inhibitor of the epigenetic modifie...
Outcomes of second round PRRT in patients with progressive refractory stage IV neuroendocrine neoplasms (NEN).
e16331 Background: Ever since approval of PRRT for NEN in 2018, our institution has administered PRRT to around 700 patien...
Respiratory failure in patients treated with immune checkpoint inhibitors.
e24169 Background: Immune checkpoint inhibitors (ICIs) are increasingly used across cancer types, yet the causes and outco...
AI-powered spatial tumor microenvironment analysis in metastatic microsatellite-stable colorectal cancer receiving immunotherapy.
2532 Background: Microsatellite-stable (MSS) colorectal cancer (CRC) is typically immune-cold, limiting the routine use of...
BC3195, a novel ADC targeting cadherin-3 (CDH3): Preliminary results of a phase I study in patients with advanced solid malignancies (study BC3195-102).
3035 Background: Cadherin-3 (CDH3), a calcium-dependent adhesion glycoprotein, is overexpressed on lung, breast, ovarian,...
Diagnostic accuracy of frozen sections for intraoperative detection of spread through air spaces in early-stage lung cancer: Systematic review and meta-analysis.
e20062 Background: Tumor spread through air spaces (STAS) is an independent predictor of recurrence and lung cancer–specif...
Race/ethnicity-stratified survival differences associated with psychotropic medication use in pancreatic cancer.
12072 Background: Pancreatic cancer is linked to poor survival and a high burden of neuropsychiatric symptoms. Psychotropi...
Oncologic outcomes following biologic therapy for immune-related cutaneous adverse events.
12156 Background: Biologic agents are increasingly used to treat immune-related cutaneous adverse events (ircAEs). However...
Outcomes of mortality and health care utilization in frail older patients with cancer receiving target therapies and/or immunotherapy.
1662 Background: ASCO & NCCN guidelines recommend geriatric assessment for cancer patients aged 65+ to identify vulner...
Mutational profile of colorectal cancer cells in patients with multiple primary cancers.
e15538 Background: Colorectal cancer (CRC) is one of the three most common malignancies and a frequent component of multip...
The effect of perioperative radiotherapy on prognosis in patients with operable rectal cancer who received neoadjuvant chemotherapy and underwent surgery.
e15681 Background: Total neoadjuvant therapy has emerged as a contemporary treatment strategy for operable rectal cancer,...
Real-world outcomes of systemic therapy in patients with anaplastic thyroid carcinoma.
e18135 Background: Anaplastic thyroid carcinoma (ATC) is a rare and highly aggressive malignancy with limited treatment op...
Clinical impact of first-line platinum plus two-day etoposide combined with immunotherapy in extensive-stage small cell lung cancer: Retrospective monocentric study—E-twoposide.
e20161 Background: Standard first line treatment for extensive-stage small cell lung cancer typically includes carboplatin...
Hippocampus avoidance versus standard prophylactic cranial irradiation for small cell lung cancer: A systematic review and meta-analysis of randomized controlled trials.
e20151 Background: Prophylactic cranial irradiation (PCI) for limited stage (LS-SCLC) or extensive stage small cell lung c...
Real-world patterns and temporal trends of first-line immunotherapy use in metastatic NSCLC in Brazil according to PD-L1 expression.
e20631 Background: First-line (1L) treatment of metastatic NSCLC has evolved rapidly with the incorporation of immune chec...